Find Clinical Trial

Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in patients operated on for varicose veins with conservation of the great saphenous vein. A multicentre, double blind randomised, placebo controlled, parallel group study. –


← Back
Study Phase

Phase 2

Therapeutic Area

Cardiovascular Diseases

Active substance/
Medical device

MICRONISED PURIFIED FLAVONOID FRACTION

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS005682
Protocol CodeCL2-05682-102
EudraCT Code2010-021270-11


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility